Parnax Lab (506128) 주식 개요파낙스 랩은 인도 및 전 세계에서 의약품을 제조 및 판매하는 회사입니다. 자세히 보기506128 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적1/6재무 건전성3/6배당0/6강점주가수익률(14.4x)이 Indian 시장(23.7x)보다 낮습니다.지난 5년 동안 수입이 매년 24.8% 증가했습니다.위험 분석부채는 operating cash flow로 충분히 감당되지 않습니다.높은 수준의 비현금 수입지난 3개월 동안 주가 변동성이 Indian 시장과 비교해 높았습니다.의미 있는 시가총액이 없습니다(₹2B)모든 위험 점검 보기506128 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,183 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG489,183 investors already sharing narrativesYour Fair Value₹Current Price₹147.551.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m5b2016201920222025202620282031Revenue ₹4.5bEarnings ₹214.0mAdvancedSet Fair ValueView all narrativesParnax Lab Limited 경쟁사Kimia BiosciencesSymbol: BSE:530313Market cap: ₹1.5bCoral LaboratoriesSymbol: BSE:524506Market cap: ₹2.1bBio Medica LaboratoriesSymbol: NSEI:BMLLMarket cap: ₹1.6bAarey Drugs & PharmaceuticalsSymbol: BSE:524412Market cap: ₹2.2b가격 이력 및 성과Parnax Lab 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹147.5552주 최고가₹182.0052주 최저가₹99.20베타0.0481개월 변동7.66%3개월 변동-7.00%1년 변동36.24%3년 변동110.49%5년 변동474.12%IPO 이후 변동1,656.55%최근 뉴스 및 업데이트New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.57b market cap, or US$16.6m).Reported Earnings • May 30Full year 2026 earnings released: EPS: ₹10.27 (vs ₹10.03 in FY 2025)Full year 2026 results: EPS: ₹10.27 (up from ₹10.03 in FY 2025). Revenue: ₹2.52b (up 34% from FY 2025). Net income: ₹117.8m (up 2.2% from FY 2025). Profit margin: 4.7% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 21Parnax Lab Limited to Report Q4, 2026 Results on May 28, 2026Parnax Lab Limited announced that they will report Q4, 2026 results on May 28, 2026Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹160, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹137, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.37 (vs ₹1.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.37 (up from ₹1.06 in 3Q 2025). Revenue: ₹639.1m (up 59% from 3Q 2025). Net income: ₹27.1m (up 124% from 3Q 2025). Profit margin: 4.2% (up from 3.0% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.더 많은 업데이트 보기Recent updatesNew Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.57b market cap, or US$16.6m).Reported Earnings • May 30Full year 2026 earnings released: EPS: ₹10.27 (vs ₹10.03 in FY 2025)Full year 2026 results: EPS: ₹10.27 (up from ₹10.03 in FY 2025). Revenue: ₹2.52b (up 34% from FY 2025). Net income: ₹117.8m (up 2.2% from FY 2025). Profit margin: 4.7% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 21Parnax Lab Limited to Report Q4, 2026 Results on May 28, 2026Parnax Lab Limited announced that they will report Q4, 2026 results on May 28, 2026Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹160, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹137, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.37 (vs ₹1.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.37 (up from ₹1.06 in 3Q 2025). Revenue: ₹639.1m (up 59% from 3Q 2025). Net income: ₹27.1m (up 124% from 3Q 2025). Profit margin: 4.2% (up from 3.0% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 05Parnax Lab Limited to Report Q3, 2026 Results on Feb 13, 2026Parnax Lab Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (65% net debt to equity). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹1.42b market cap, or US$15.5m).Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹3.15 (vs ₹2.97 in 2Q 2025)Second quarter 2026 results: EPS: ₹3.15 (up from ₹2.97 in 2Q 2025). Revenue: ₹632.3m (up 31% from 2Q 2025). Net income: ₹36.3m (up 6.5% from 2Q 2025). Profit margin: 5.7% (down from 7.0% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.공고 • Nov 03Parnax Lab Limited to Report Q2, 2026 Results on Nov 14, 2025Parnax Lab Limited announced that they will report Q2, 2026 results on Nov 14, 2025공고 • Aug 14Parnax Lab Limited, Annual General Meeting, Sep 29, 2025Parnax Lab Limited, Annual General Meeting, Sep 29, 2025.Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹2.85 (vs ₹3.47 in 1Q 2025)First quarter 2026 results: EPS: ₹2.85 (down from ₹3.47 in 1Q 2025). Revenue: ₹535.6m (up 6.9% from 1Q 2025). Net income: ₹32.7m (down 18% from 1Q 2025). Profit margin: 6.1% (down from 7.9% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 8% per year.공고 • Aug 06Parnax Lab Limited to Report Q1, 2026 Results on Aug 13, 2025Parnax Lab Limited announced that they will report Q1, 2026 results on Aug 13, 2025Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹126, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹111, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.7% over the past three years.Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹10.05 (vs ₹8.37 in FY 2024)Full year 2025 results: EPS: ₹10.05 (up from ₹8.37 in FY 2024). Revenue: ₹1.89b (flat on FY 2024). Net income: ₹115.2m (up 20% from FY 2024). Profit margin: 6.1% (up from 5.1% in FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.공고 • May 20Parnax Lab Limited to Report Q4, 2025 Results on May 27, 2025Parnax Lab Limited announced that they will report Q4, 2025 results on May 27, 2025Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 21% over the past three years.공고 • Mar 21Parnax Lab Limited Announces Executive ChangesParnax Lab Limited at its meeting had inter-alia considered and approved the following: Special Resolution: Appointment of Mr. Vijay Kumar Ayare (DIN: 06383445) as a Non- Executive & Independent Director of the Company, on the Board of the Company, by the Shareholders to hold office for a term up to 5 (five) consecutive years from the date of appointment i. e. 10 February, 2025 to 09 February, 2030, not liable to retire by rotation. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Mihir P. Shah, as a Managing Director and CEO, from Director and CEO of the Company. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Binoy B. Shah, as an Executive Director and CFO, from Managing Director and CFO of the Company. Mr. Vijay Kumar Ayare is having 50+ years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Wanbury Group. Mr. Vijay Kumar Ayare is committed to harnessing the growth potential of Wanbury Group by catering to the demands of the industry with professionalism and a differentiated service offering. At the core of Wanbury Group, Mr. Vijay Kumar Ayare is one of the qualified and passionate in management team, who has behind him skill and experience. It is as a result of his diligence and perseverance that Wanbury's prowess in pharmaceutical manufacturing has seen exponential growth and achievement. He is Diligent in Strategy and planning, Deal Evaluation and Structuring.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹1.06 (vs ₹1.90 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.06 (down from ₹1.90 in 3Q 2024). Revenue: ₹404.1m (down 21% from 3Q 2024). Net income: ₹12.1m (down 44% from 3Q 2024). Profit margin: 3.0% (down from 4.3% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 01Parnax Lab Limited to Report Q3, 2025 Results on Feb 10, 2025Parnax Lab Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 10, 2025Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹178, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 408% over the past three years.Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹2.97 (vs ₹1.63 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.97 (up from ₹1.63 in 2Q 2024). Revenue: ₹493.1m (up 16% from 2Q 2024). Net income: ₹34.1m (up 82% from 2Q 2024). Profit margin: 6.9% (up from 4.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹2.07b market cap, or US$24.5m).공고 • Nov 07Parnax Lab Limited to Report Q2, 2025 Results on Nov 14, 2024Parnax Lab Limited announced that they will report Q2, 2025 results on Nov 14, 2024Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹180, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 623% over the past three years.Valuation Update With 7 Day Price Move • Oct 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹157, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 40x in the Pharmaceuticals industry in India. Total returns to shareholders of 525% over the past three years.New Risk • Aug 19New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 20% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (₹1.13b market cap, or US$13.5m).공고 • Aug 16Parnax Lab Limited, Annual General Meeting, Sep 28, 2024Parnax Lab Limited, Annual General Meeting, Sep 28, 2024.Reported Earnings • Aug 16First quarter 2025 earnings released: EPS: ₹3.47 (vs ₹2.90 in 1Q 2024)First quarter 2025 results: EPS: ₹3.47 (up from ₹2.90 in 1Q 2024). Revenue: ₹502.3m (up 3.1% from 1Q 2024). Net income: ₹39.8m (up 20% from 1Q 2024). Profit margin: 7.9% (up from 6.8% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.공고 • Aug 05Parnax Lab Limited to Report Q1, 2025 Results on Aug 14, 2024Parnax Lab Limited announced that they will report Q1, 2025 results on Aug 14, 2024Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹109, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 351% over the past three years.Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹113, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 310% over the past three years.Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹8.38 (vs ₹7.79 in FY 2023)Full year 2024 results: EPS: ₹8.38 (up from ₹7.79 in FY 2023). Revenue: ₹1.90b (up 13% from FY 2023). Net income: ₹96.1m (up 12% from FY 2023). Profit margin: 5.1% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.공고 • May 24Parnax Lab Limited to Report Q4, 2024 Results on May 30, 2024Parnax Lab Limited announced that they will report Q4, 2024 results on May 30, 2024Buy Or Sell Opportunity • May 23Now 21% undervaluedOver the last 90 days, the stock has risen 26% to ₹109. The fair value is estimated to be ₹139, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%.Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹151, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 646% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹132, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 551% over the past three years.New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.29b market cap, or US$15.5m).Buy Or Sell Opportunity • Mar 15Now 23% undervaluedOver the last 90 days, the stock has risen 24% to ₹108. The fair value is estimated to be ₹140, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹109, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 382% over the past three years.Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹1.90 (vs ₹2.96 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.90 (down from ₹2.96 in 3Q 2023). Revenue: ₹510.9m (up 9.1% from 3Q 2023). Net income: ₹21.8m (down 31% from 3Q 2023). Profit margin: 4.3% (down from 6.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.공고 • Feb 04Parnax Lab Limited to Report Q3, 2024 Results on Feb 13, 2024Parnax Lab Limited announced that they will report Q3, 2024 results on Feb 13, 2024Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.07, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 239% over the past three years.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹1.63 (vs ₹1.83 in 2Q 2023)Second quarter 2024 results: EPS: ₹1.63 (down from ₹1.83 in 2Q 2023). Revenue: ₹428.3m (flat on 2Q 2023). Net income: ₹18.7m (down 11% from 2Q 2023). Profit margin: 4.4% (down from 4.9% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₹114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.공고 • Nov 04Parnax Lab Limited to Report Q2, 2024 Results on Nov 09, 2023Parnax Lab Limited announced that they will report Q2, 2024 results on Nov 09, 2023Buying Opportunity • Oct 20Now 21% undervaluedOver the last 90 days, the stock is up 29%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.공고 • Oct 01Parnax Lab Limited Appoints Harish S. Panpalia as a Non-Executive Independent DirectorParnax Lab Limited announced that the Board of Directors of the Company at its meeting held on 29th September, 2023 has Appointed Mr. Harish S. Panpalia (DIN: 10275561) as a Non-Executive Independent Director of the Company, for a consecutive period of Five (5) years, effective 11th August, 2023. Date of Birth: October 24, 1959. Qualification: Masters from Nagpur University, Diploma in Business Management, CAIIB. BS Trainer. Occupation: SERVICE & COPRPORATE ADVISORY. Experience: Seasoned Corporate Banking Professional with more than 39 years of successful career with SBI. Retired in Top Executive Grade in 2019 and since working as Senior Vice President (Debt Syndication) with Pranjal Corporate Services, an Investment Boutique Firm in Mumbai; Specialized in the domain of Corporate Credit, Stress Asset Management, Risk Management, Branch Management; Played a key role in arranging high value credit requirement of various Listed and Large/Medium Corporates; Guided many Corporate Houses for improvisation in Balance sheet and reduction of funding cost, etc; Headed various large size branches of SBI & gained adequate expertise of Administration and resources management; Diligent in Strategy and planning, Deal Evaluation and Structuring; Expertise in handling Restructuring, OTS and Merger and Acquisitions; Good liaison and network in banking sector.Buying Opportunity • Sep 20Now 21% undervaluedOver the last 90 days, the stock is up 48%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹95.55, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 505% over the past three years.Buying Opportunity • Aug 23Now 21% undervaluedOver the last 90 days, the stock is up 28%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹2.90 (vs ₹1.97 in 1Q 2023)First quarter 2024 results: EPS: ₹2.90 (up from ₹1.97 in 1Q 2023). Revenue: ₹489.9m (up 33% from 1Q 2023). Net income: ₹33.2m (up 72% from 1Q 2023). Profit margin: 6.8% (up from 5.3% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth.공고 • Aug 12Parnax Lab Limited, Annual General Meeting, Sep 29, 2023Parnax Lab Limited, Annual General Meeting, Sep 29, 2023.Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹91.94, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 384% over the past three years.공고 • Aug 04Parnax Lab Limited to Report Q1, 2024 Results on Aug 11, 2023Parnax Lab Limited announced that they will report Q1, 2024 results on Aug 11, 2023Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹68.36, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 297% over the past three years.Reported Earnings • Jun 04Full year 2023 earnings released: EPS: ₹7.80 (vs ₹9.68 in FY 2022)Full year 2023 results: EPS: ₹7.80. Revenue: ₹1.68b (up 3.3% from FY 2022). Net income: ₹86.2m (up 4.6% from FY 2022). Profit margin: 5.1% (in line with FY 2022).공고 • May 23Parnax Lab Limited to Report Fiscal Year 2023 Results on May 30, 2023Parnax Lab Limited announced that they will report fiscal year 2023 results on May 30, 2023Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₹75.69, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 281% over the past three years.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹2.96 (vs ₹5.37 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.96 (down from ₹5.37 in 3Q 2022). Revenue: ₹468.2m (down 7.6% from 3Q 2022). Net income: ₹31.5m (down 31% from 3Q 2022). Profit margin: 6.7% (down from 9.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 71% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 444% over the past three years.공고 • Feb 06Parnax Lab Limited to Report Q3, 2023 Results on Feb 14, 2023Parnax Lab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023공고 • Sep 07Parnax Lab Limited, Annual General Meeting, Sep 28, 2022Parnax Lab Limited, Annual General Meeting, Sep 28, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the audited standalone financial statements of the company for the financial year ended 31 march 2022; to consider re-appointment of Mr. Prakash Shah as a director to retire by rotation.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: ₹1.97 (vs ₹1.15 in 1Q 2022)First quarter 2023 results: EPS: ₹1.97 (up from ₹1.15 in 1Q 2022). Revenue: ₹368.6m (up 28% from 1Q 2022). Net income: ₹19.3m (up 98% from 1Q 2022). Profit margin: 5.2% (up from 3.4% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.공고 • Aug 03Parnax Lab Limited to Report Q1, 2023 Results on Aug 10, 2022Parnax Lab Limited announced that they will report Q1, 2023 results on Aug 10, 2022Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 312% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹85.60, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 214% over the past three years.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹105, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 288% over the past three years.Reported Earnings • Jun 02Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹9.70 (up from ₹0.43 loss in FY 2021). Revenue: ₹1.63b (up 81% from FY 2021). Net income: ₹82.4m (up ₹86.1m from FY 2021). Profit margin: 5.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 56% per year.공고 • May 24Parnax Lab Limited to Report Q4, 2022 Results on May 30, 2022Parnax Lab Limited announced that they will report Q4, 2022 results on May 30, 2022Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹134, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 356% over the past three years.Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹135, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹102, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years.Reported Earnings • Feb 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹5.37 (up from ₹0.14 in 3Q 2021). Revenue: ₹506.8m (up 104% from 3Q 2021). Net income: ₹45.5m (up ₹44.4m from 3Q 2021). Profit margin: 9.0% (up from 0.5% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 08Parnax Lab Limited to Report Q3, 2022 Results on Feb 14, 2022Parnax Lab Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹76.05, the stock trades at a trailing P/E ratio of 75.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 86% over the past three years.공고 • Jan 03Parnax Lab Limited announced that it expects to receive INR 45.78375 million in fundingParnax Lab Limited announced a private placement of 4,210,000 pre-paid warrants at an issue price of INR 10.875 for gross proceeds of INR 45,783,750 on January 1, 2022. The transaction will involve participation from individual investors, Prakash Shah, Pragna Prakash Shah, Mihir Prakash Shah, Ami Mihir Prakash Shah for 526,250 warrants each, Baiju Mahashukhlal, Ila Baiju Shah for 701,000 warrants each, and Shah Binoy Baiju for 703,000 warrants. The warrants are convertible into shares at INR 10 each. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹52.75, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹42.25, the stock trades at a trailing P/E ratio of 41.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 10% over the past three years.Reported Earnings • Nov 18Second quarter 2022 earnings released: EPS ₹3.38 (vs ₹2.82 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹358.2m (up 34% from 2Q 2021). Net income: ₹28.7m (up 20% from 2Q 2021). Profit margin: 8.0% (down from 9.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹28.95, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹31.70, the stock trades at a trailing P/E ratio of 70.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.7% over the past three years.Reported Earnings • Jul 04Full year 2021 earnings released: ₹0.42 loss per share (vs ₹3.43 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: ₹897.3m (down 6.1% from FY 2020). Net loss: ₹3.62m (loss narrowed 88% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Executive Departure • Jun 08Company Secretary & Compliance Officer Namrata Kambli has left the companyOn the 31st of May, Namrata Kambli's tenure as Company Secretary & Compliance Officer ended after 1.5 years in the role. We don't have any record of a personal shareholding under Namrata's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.Executive Departure • Mar 10Independent & Non-Executive Director has left the companyOn the 27th of February, Manharbhai Jhavari's tenure as Independent & Non-Executive Director ended after 9.6 years in the role. We don't have any record of a personal shareholding under Manharbhai's name. Manharbhai is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.14 (vs ₹0.97 loss in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹248.3m (down 2.9% from 3Q 2020). Net income: ₹1.15m (up ₹9.38m from 3Q 2020). Profit margin: 0.5% (up from net loss in 3Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 77% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 09New 90-day high: ₹37.30The company is up 103% from its price of ₹18.35 on 11 November 2020. The Indian market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period.공고 • Feb 03Parnax Lab Limited to Report Q3, 2021 Results on Feb 13, 2021Parnax Lab Limited announced that they will report Q3, 2021 results on Feb 13, 2021Is New 90 Day High Low • Jan 25New 90-day high: ₹31.20The company is up 68% from its price of ₹18.60 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Is New 90 Day High Low • Dec 09New 90-day high: ₹30.30The company is up 72% from its price of ₹17.65 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day high: ₹21.10The company is up 11% from its price of ₹19.00 on 14 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Reported Earnings • Sep 19First quarter earnings releasedOver the last 12 months the company has reported total losses of ₹27.6m, with earnings decreasing by ₹53.7m from the prior year. Total revenue was ₹923.0m over the last 12 months, down 15% from the prior year.공고 • Sep 05Parnax Lab Limited to Report Q1, 2021 Results on Sep 15, 2020Parnax Lab Limited announced that they will report Q1, 2021 results on Sep 15, 2020공고 • Jun 21Parnax Lab Limited to Report Q4, 2020 Results on Jun 30, 2020Parnax Lab Limited announced that they will report Q4, 2020 results on Jun 30, 2020주주 수익률506128IN PharmaceuticalsIN 시장7D3.4%-0.8%-0.2%1Y36.2%10.5%-0.5%전체 주주 수익률 보기수익률 대 산업: 506128은 지난 1년 동안 10.5%의 수익을 기록한 Indian Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 506128은 지난 1년 동안 -0.5%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 506128's price volatile compared to industry and market?506128 volatility506128 Average Weekly Movement7.8%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.0%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.8%안정적인 주가: 506128의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: 506128의 주간 변동성(8%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트198212Mihir Shahwww.naxparlab.com파낙스 랩은 인도 및 국제적으로 의약품을 제조 및 판매하는 회사입니다. 이 회사는 액체, 연고, 젤, 크림, 정제, 캡슐 형태의 의약품과 의약품을 제공합니다. 화장품, 허브, 건강기능식품도 제공합니다.더 보기Parnax Lab Limited 기초 지표 요약Parnax Lab의 순이익과 매출은 시가총액과 어떻게 비교됩니까?506128 기초 통계시가총액₹1.69b순이익 (TTM)₹117.77m매출 (TTM)₹2.49b14.4x주가수익비율(P/E)0.7x주가매출비율(P/S)506128는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표506128 손익계산서 (TTM)매출₹2.49b매출원가₹1.47b총이익₹1.01b기타 비용₹896.78m순이익₹117.77m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)10.25총이익률40.82%순이익률4.74%부채/자본 비율78.2%506128의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/19 12:41종가2026/07/17 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Parnax Lab Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Vinayak M.FirstCall Research
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.57b market cap, or US$16.6m).
Reported Earnings • May 30Full year 2026 earnings released: EPS: ₹10.27 (vs ₹10.03 in FY 2025)Full year 2026 results: EPS: ₹10.27 (up from ₹10.03 in FY 2025). Revenue: ₹2.52b (up 34% from FY 2025). Net income: ₹117.8m (up 2.2% from FY 2025). Profit margin: 4.7% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 21Parnax Lab Limited to Report Q4, 2026 Results on May 28, 2026Parnax Lab Limited announced that they will report Q4, 2026 results on May 28, 2026
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹160, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹137, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.37 (vs ₹1.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.37 (up from ₹1.06 in 3Q 2025). Revenue: ₹639.1m (up 59% from 3Q 2025). Net income: ₹27.1m (up 124% from 3Q 2025). Profit margin: 4.2% (up from 3.0% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.57b market cap, or US$16.6m).
Reported Earnings • May 30Full year 2026 earnings released: EPS: ₹10.27 (vs ₹10.03 in FY 2025)Full year 2026 results: EPS: ₹10.27 (up from ₹10.03 in FY 2025). Revenue: ₹2.52b (up 34% from FY 2025). Net income: ₹117.8m (up 2.2% from FY 2025). Profit margin: 4.7% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 21Parnax Lab Limited to Report Q4, 2026 Results on May 28, 2026Parnax Lab Limited announced that they will report Q4, 2026 results on May 28, 2026
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹160, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹137, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 171% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.37 (vs ₹1.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.37 (up from ₹1.06 in 3Q 2025). Revenue: ₹639.1m (up 59% from 3Q 2025). Net income: ₹27.1m (up 124% from 3Q 2025). Profit margin: 4.2% (up from 3.0% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 05Parnax Lab Limited to Report Q3, 2026 Results on Feb 13, 2026Parnax Lab Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (65% net debt to equity). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹1.42b market cap, or US$15.5m).
Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹3.15 (vs ₹2.97 in 2Q 2025)Second quarter 2026 results: EPS: ₹3.15 (up from ₹2.97 in 2Q 2025). Revenue: ₹632.3m (up 31% from 2Q 2025). Net income: ₹36.3m (up 6.5% from 2Q 2025). Profit margin: 5.7% (down from 7.0% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Nov 03Parnax Lab Limited to Report Q2, 2026 Results on Nov 14, 2025Parnax Lab Limited announced that they will report Q2, 2026 results on Nov 14, 2025
공고 • Aug 14Parnax Lab Limited, Annual General Meeting, Sep 29, 2025Parnax Lab Limited, Annual General Meeting, Sep 29, 2025.
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹2.85 (vs ₹3.47 in 1Q 2025)First quarter 2026 results: EPS: ₹2.85 (down from ₹3.47 in 1Q 2025). Revenue: ₹535.6m (up 6.9% from 1Q 2025). Net income: ₹32.7m (down 18% from 1Q 2025). Profit margin: 6.1% (down from 7.9% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 8% per year.
공고 • Aug 06Parnax Lab Limited to Report Q1, 2026 Results on Aug 13, 2025Parnax Lab Limited announced that they will report Q1, 2026 results on Aug 13, 2025
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹126, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹111, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.7% over the past three years.
Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹10.05 (vs ₹8.37 in FY 2024)Full year 2025 results: EPS: ₹10.05 (up from ₹8.37 in FY 2024). Revenue: ₹1.89b (flat on FY 2024). Net income: ₹115.2m (up 20% from FY 2024). Profit margin: 6.1% (up from 5.1% in FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
공고 • May 20Parnax Lab Limited to Report Q4, 2025 Results on May 27, 2025Parnax Lab Limited announced that they will report Q4, 2025 results on May 27, 2025
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 21% over the past three years.
공고 • Mar 21Parnax Lab Limited Announces Executive ChangesParnax Lab Limited at its meeting had inter-alia considered and approved the following: Special Resolution: Appointment of Mr. Vijay Kumar Ayare (DIN: 06383445) as a Non- Executive & Independent Director of the Company, on the Board of the Company, by the Shareholders to hold office for a term up to 5 (five) consecutive years from the date of appointment i. e. 10 February, 2025 to 09 February, 2030, not liable to retire by rotation. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Mihir P. Shah, as a Managing Director and CEO, from Director and CEO of the Company. Ordinary Resolution: Upon the recommendation of the Nomination and Remuneration Committee (NRC) & approved by the Board of Directors in their NRC & Board Meeting dated November 14, 2024, the Ratification of Change of Designation of Mr. Binoy B. Shah, as an Executive Director and CFO, from Managing Director and CFO of the Company. Mr. Vijay Kumar Ayare is having 50+ years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Wanbury Group. Mr. Vijay Kumar Ayare is committed to harnessing the growth potential of Wanbury Group by catering to the demands of the industry with professionalism and a differentiated service offering. At the core of Wanbury Group, Mr. Vijay Kumar Ayare is one of the qualified and passionate in management team, who has behind him skill and experience. It is as a result of his diligence and perseverance that Wanbury's prowess in pharmaceutical manufacturing has seen exponential growth and achievement. He is Diligent in Strategy and planning, Deal Evaluation and Structuring.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to ₹102, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.
Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹1.06 (vs ₹1.90 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.06 (down from ₹1.90 in 3Q 2024). Revenue: ₹404.1m (down 21% from 3Q 2024). Net income: ₹12.1m (down 44% from 3Q 2024). Profit margin: 3.0% (down from 4.3% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 01Parnax Lab Limited to Report Q3, 2025 Results on Feb 10, 2025Parnax Lab Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 10, 2025
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹178, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 408% over the past three years.
Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹2.97 (vs ₹1.63 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.97 (up from ₹1.63 in 2Q 2024). Revenue: ₹493.1m (up 16% from 2Q 2024). Net income: ₹34.1m (up 82% from 2Q 2024). Profit margin: 6.9% (up from 4.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹2.07b market cap, or US$24.5m).
공고 • Nov 07Parnax Lab Limited to Report Q2, 2025 Results on Nov 14, 2024Parnax Lab Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹180, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 623% over the past three years.
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹157, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 40x in the Pharmaceuticals industry in India. Total returns to shareholders of 525% over the past three years.
New Risk • Aug 19New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 20% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (20% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (₹1.13b market cap, or US$13.5m).
공고 • Aug 16Parnax Lab Limited, Annual General Meeting, Sep 28, 2024Parnax Lab Limited, Annual General Meeting, Sep 28, 2024.
Reported Earnings • Aug 16First quarter 2025 earnings released: EPS: ₹3.47 (vs ₹2.90 in 1Q 2024)First quarter 2025 results: EPS: ₹3.47 (up from ₹2.90 in 1Q 2024). Revenue: ₹502.3m (up 3.1% from 1Q 2024). Net income: ₹39.8m (up 20% from 1Q 2024). Profit margin: 7.9% (up from 6.8% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Aug 05Parnax Lab Limited to Report Q1, 2025 Results on Aug 14, 2024Parnax Lab Limited announced that they will report Q1, 2025 results on Aug 14, 2024
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹109, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 351% over the past three years.
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹113, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 310% over the past three years.
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹8.38 (vs ₹7.79 in FY 2023)Full year 2024 results: EPS: ₹8.38 (up from ₹7.79 in FY 2023). Revenue: ₹1.90b (up 13% from FY 2023). Net income: ₹96.1m (up 12% from FY 2023). Profit margin: 5.1% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
공고 • May 24Parnax Lab Limited to Report Q4, 2024 Results on May 30, 2024Parnax Lab Limited announced that they will report Q4, 2024 results on May 30, 2024
Buy Or Sell Opportunity • May 23Now 21% undervaluedOver the last 90 days, the stock has risen 26% to ₹109. The fair value is estimated to be ₹139, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%.
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹151, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 646% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹132, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 551% over the past three years.
New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.29b market cap, or US$15.5m).
Buy Or Sell Opportunity • Mar 15Now 23% undervaluedOver the last 90 days, the stock has risen 24% to ₹108. The fair value is estimated to be ₹140, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 54%.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹109, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 382% over the past three years.
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹1.90 (vs ₹2.96 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.90 (down from ₹2.96 in 3Q 2023). Revenue: ₹510.9m (up 9.1% from 3Q 2023). Net income: ₹21.8m (down 31% from 3Q 2023). Profit margin: 4.3% (down from 6.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.
공고 • Feb 04Parnax Lab Limited to Report Q3, 2024 Results on Feb 13, 2024Parnax Lab Limited announced that they will report Q3, 2024 results on Feb 13, 2024
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.07, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 239% over the past three years.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹1.63 (vs ₹1.83 in 2Q 2023)Second quarter 2024 results: EPS: ₹1.63 (down from ₹1.83 in 2Q 2023). Revenue: ₹428.3m (flat on 2Q 2023). Net income: ₹18.7m (down 11% from 2Q 2023). Profit margin: 4.4% (down from 4.9% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₹114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
공고 • Nov 04Parnax Lab Limited to Report Q2, 2024 Results on Nov 09, 2023Parnax Lab Limited announced that they will report Q2, 2024 results on Nov 09, 2023
Buying Opportunity • Oct 20Now 21% undervaluedOver the last 90 days, the stock is up 29%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
공고 • Oct 01Parnax Lab Limited Appoints Harish S. Panpalia as a Non-Executive Independent DirectorParnax Lab Limited announced that the Board of Directors of the Company at its meeting held on 29th September, 2023 has Appointed Mr. Harish S. Panpalia (DIN: 10275561) as a Non-Executive Independent Director of the Company, for a consecutive period of Five (5) years, effective 11th August, 2023. Date of Birth: October 24, 1959. Qualification: Masters from Nagpur University, Diploma in Business Management, CAIIB. BS Trainer. Occupation: SERVICE & COPRPORATE ADVISORY. Experience: Seasoned Corporate Banking Professional with more than 39 years of successful career with SBI. Retired in Top Executive Grade in 2019 and since working as Senior Vice President (Debt Syndication) with Pranjal Corporate Services, an Investment Boutique Firm in Mumbai; Specialized in the domain of Corporate Credit, Stress Asset Management, Risk Management, Branch Management; Played a key role in arranging high value credit requirement of various Listed and Large/Medium Corporates; Guided many Corporate Houses for improvisation in Balance sheet and reduction of funding cost, etc; Headed various large size branches of SBI & gained adequate expertise of Administration and resources management; Diligent in Strategy and planning, Deal Evaluation and Structuring; Expertise in handling Restructuring, OTS and Merger and Acquisitions; Good liaison and network in banking sector.
Buying Opportunity • Sep 20Now 21% undervaluedOver the last 90 days, the stock is up 48%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹95.55, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 505% over the past three years.
Buying Opportunity • Aug 23Now 21% undervaluedOver the last 90 days, the stock is up 28%. The fair value is estimated to be ₹115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹2.90 (vs ₹1.97 in 1Q 2023)First quarter 2024 results: EPS: ₹2.90 (up from ₹1.97 in 1Q 2023). Revenue: ₹489.9m (up 33% from 1Q 2023). Net income: ₹33.2m (up 72% from 1Q 2023). Profit margin: 6.8% (up from 5.3% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth.
공고 • Aug 12Parnax Lab Limited, Annual General Meeting, Sep 29, 2023Parnax Lab Limited, Annual General Meeting, Sep 29, 2023.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹91.94, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 384% over the past three years.
공고 • Aug 04Parnax Lab Limited to Report Q1, 2024 Results on Aug 11, 2023Parnax Lab Limited announced that they will report Q1, 2024 results on Aug 11, 2023
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹68.36, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 297% over the past three years.
Reported Earnings • Jun 04Full year 2023 earnings released: EPS: ₹7.80 (vs ₹9.68 in FY 2022)Full year 2023 results: EPS: ₹7.80. Revenue: ₹1.68b (up 3.3% from FY 2022). Net income: ₹86.2m (up 4.6% from FY 2022). Profit margin: 5.1% (in line with FY 2022).
공고 • May 23Parnax Lab Limited to Report Fiscal Year 2023 Results on May 30, 2023Parnax Lab Limited announced that they will report fiscal year 2023 results on May 30, 2023
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₹75.69, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 281% over the past three years.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹2.96 (vs ₹5.37 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.96 (down from ₹5.37 in 3Q 2022). Revenue: ₹468.2m (down 7.6% from 3Q 2022). Net income: ₹31.5m (down 31% from 3Q 2022). Profit margin: 6.7% (down from 9.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 71% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 444% over the past three years.
공고 • Feb 06Parnax Lab Limited to Report Q3, 2023 Results on Feb 14, 2023Parnax Lab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023
공고 • Sep 07Parnax Lab Limited, Annual General Meeting, Sep 28, 2022Parnax Lab Limited, Annual General Meeting, Sep 28, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the audited standalone financial statements of the company for the financial year ended 31 march 2022; to consider re-appointment of Mr. Prakash Shah as a director to retire by rotation.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: ₹1.97 (vs ₹1.15 in 1Q 2022)First quarter 2023 results: EPS: ₹1.97 (up from ₹1.15 in 1Q 2022). Revenue: ₹368.6m (up 28% from 1Q 2022). Net income: ₹19.3m (up 98% from 1Q 2022). Profit margin: 5.2% (up from 3.4% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth.
공고 • Aug 03Parnax Lab Limited to Report Q1, 2023 Results on Aug 10, 2022Parnax Lab Limited announced that they will report Q1, 2023 results on Aug 10, 2022
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 312% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹85.60, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 214% over the past three years.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹105, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 288% over the past three years.
Reported Earnings • Jun 02Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹9.70 (up from ₹0.43 loss in FY 2021). Revenue: ₹1.63b (up 81% from FY 2021). Net income: ₹82.4m (up ₹86.1m from FY 2021). Profit margin: 5.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 56% per year.
공고 • May 24Parnax Lab Limited to Report Q4, 2022 Results on May 30, 2022Parnax Lab Limited announced that they will report Q4, 2022 results on May 30, 2022
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹134, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 356% over the past three years.
Valuation Update With 7 Day Price Move • Mar 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹135, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹102, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years.
Reported Earnings • Feb 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹5.37 (up from ₹0.14 in 3Q 2021). Revenue: ₹506.8m (up 104% from 3Q 2021). Net income: ₹45.5m (up ₹44.4m from 3Q 2021). Profit margin: 9.0% (up from 0.5% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 08Parnax Lab Limited to Report Q3, 2022 Results on Feb 14, 2022Parnax Lab Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹76.05, the stock trades at a trailing P/E ratio of 75.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 86% over the past three years.
공고 • Jan 03Parnax Lab Limited announced that it expects to receive INR 45.78375 million in fundingParnax Lab Limited announced a private placement of 4,210,000 pre-paid warrants at an issue price of INR 10.875 for gross proceeds of INR 45,783,750 on January 1, 2022. The transaction will involve participation from individual investors, Prakash Shah, Pragna Prakash Shah, Mihir Prakash Shah, Ami Mihir Prakash Shah for 526,250 warrants each, Baiju Mahashukhlal, Ila Baiju Shah for 701,000 warrants each, and Shah Binoy Baiju for 703,000 warrants. The warrants are convertible into shares at INR 10 each. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹52.75, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹42.25, the stock trades at a trailing P/E ratio of 41.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 10% over the past three years.
Reported Earnings • Nov 18Second quarter 2022 earnings released: EPS ₹3.38 (vs ₹2.82 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹358.2m (up 34% from 2Q 2021). Net income: ₹28.7m (up 20% from 2Q 2021). Profit margin: 8.0% (down from 9.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹28.95, the stock trades at a trailing P/E ratio of 64.6x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹31.70, the stock trades at a trailing P/E ratio of 70.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.7% over the past three years.
Reported Earnings • Jul 04Full year 2021 earnings released: ₹0.42 loss per share (vs ₹3.43 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: ₹897.3m (down 6.1% from FY 2020). Net loss: ₹3.62m (loss narrowed 88% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Executive Departure • Jun 08Company Secretary & Compliance Officer Namrata Kambli has left the companyOn the 31st of May, Namrata Kambli's tenure as Company Secretary & Compliance Officer ended after 1.5 years in the role. We don't have any record of a personal shareholding under Namrata's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.
Executive Departure • Mar 10Independent & Non-Executive Director has left the companyOn the 27th of February, Manharbhai Jhavari's tenure as Independent & Non-Executive Director ended after 9.6 years in the role. We don't have any record of a personal shareholding under Manharbhai's name. Manharbhai is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 15Third quarter 2021 earnings released: EPS ₹0.14 (vs ₹0.97 loss in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹248.3m (down 2.9% from 3Q 2020). Net income: ₹1.15m (up ₹9.38m from 3Q 2020). Profit margin: 0.5% (up from net loss in 3Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 77% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 09New 90-day high: ₹37.30The company is up 103% from its price of ₹18.35 on 11 November 2020. The Indian market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period.
공고 • Feb 03Parnax Lab Limited to Report Q3, 2021 Results on Feb 13, 2021Parnax Lab Limited announced that they will report Q3, 2021 results on Feb 13, 2021
Is New 90 Day High Low • Jan 25New 90-day high: ₹31.20The company is up 68% from its price of ₹18.60 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Dec 09New 90-day high: ₹30.30The company is up 72% from its price of ₹17.65 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day high: ₹21.10The company is up 11% from its price of ₹19.00 on 14 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Reported Earnings • Sep 19First quarter earnings releasedOver the last 12 months the company has reported total losses of ₹27.6m, with earnings decreasing by ₹53.7m from the prior year. Total revenue was ₹923.0m over the last 12 months, down 15% from the prior year.
공고 • Sep 05Parnax Lab Limited to Report Q1, 2021 Results on Sep 15, 2020Parnax Lab Limited announced that they will report Q1, 2021 results on Sep 15, 2020
공고 • Jun 21Parnax Lab Limited to Report Q4, 2020 Results on Jun 30, 2020Parnax Lab Limited announced that they will report Q4, 2020 results on Jun 30, 2020
